Comparative Pharmacology
Head-to-head clinical analysis: HEDULIN versus HEPARIN LOCK FLUSH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEDULIN versus HEPARIN LOCK FLUSH.
HEDULIN vs HEPARIN LOCK FLUSH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEDULIN (phenindione) is an anticoagulant that inhibits vitamin K-dependent synthesis of coagulation factors II, VII, IX, and X in the liver, thereby reducing thrombus formation.
Heparin potentiates the activity of antithrombin III, inactivating thrombin and activated factor X (FXa), thereby preventing fibrin formation and thrombus propagation.
Oral, 200-400 mg initially, then 100-200 mg every 6-12 hours; maximum daily dose 1200 mg.
10-100 units/mL solution, 1-2 mL flush intravascularly after each catheter use or daily when catheter is not in use; typical adult dose: 10-100 units per flush.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in patients with normal renal function; may be prolonged to 30-40 hours in renal impairment, necessitating dose adjustment.
Terminal elimination half-life approximately 1-2 hours (mean 1.5 hours) at therapeutic doses; increases with dose; in renal failure, half-life prolonged up to 3-5 hours; clinical note: duration of effect short due to rapid clearance, requiring continuous infusion or frequent dosing.
Renal excretion of unchanged drug accounts for approximately 70% of elimination; the remainder is metabolized hepatically and excreted in feces via bile.
Primarily renal via glomerular filtration and tubular secretion; about 50% excreted unchanged in urine; remainder metabolized in the liver and reticuloendothelial system (heparinase); fecal elimination negligible (<5%).
Category C
Category A/B
Anticoagulant
Anticoagulant